Purpose: Conducting an objective evidence-based olfactometric study. Respiratory dysfunction diagnosis. Monitoring the effectiveness of rhinosurgical interventions. Monitoring the intensity of rehabilitation after COVID-19. Sports medicine.
Description: For the first time it is proposed to combine rhinomanometry and olfactometry. Until now, there has been no such unique collection in the medical device markets. It is this combination that allows comprehensive testing of breathing disorders. The technology “changes and expands” the olfactory sensitivity; there is no need to rely entirely on the patient’s subjective responses about what he or she does not smell. It is important to apply test results to planning and forecasting operations. A tool for assessing the correctness of surgical intervention is proposed. A criterion of olfactory sensitivity based on changes in the nasal breathing regime has been introduced. Rhinomanometry gives the energy characteristics of nasal breathing at the time of smelling. After a series of mathematical transformations, a certain number is displayed and, according to the developed classification, it is determined to which the violation belongs (norm, weak, medium dysosmia). Conducted before / after operational research; comparison of characteristics takes place; a conclusion is made on the level of success of the intervention.
Technical characteristics: There are various methods and tools for assessing the sense of smell, but they are all subjective – they boil down to the usual assessment of the response to the smell of the supplied air. According to the WHO, 75% of upper respiratory tract diseases are caused by metabolic disorders in the body. However, patients rarely go to doctors with complaints only of a violation of the sense of smell. If the same disorders caused by respiratory pathogenesis are not identified and treated in a timely manner, this can contribute to chronic disease and complete atrophy of the olfactory analyzer.
Advantages: There are no analogues for measuring the sensitivity of smell based on rhinomanometry. The device relies on the measured quantities and mathematical calculations used, not on the patient’s responses. Both olfactory disorders and breathing disorders are objectively tested.
Estimated development cost: € 10,000.
Development readiness stage: The prototype of the device and the application technology developed. Metrological certification for the measuring device received.
Transfer opportunity: Technology transfer. Creation of joint ventures on the territory of Ukraine or abroad.
Novelty: 1 patent of Ukraine.
IF YOU ARE INTERESTED IN THIS DEVELOPMENT, PLEASE,